OPGx-MERTK / Opus Genetics - LARVOL DELTA

OPGx-MERTK - Advancing with Non-Dilutive Support (The Manila Times) - "Non-dilutive funding up to $2 million received from the Retinal Degeneration Fund to advance OPGx-MERTK, targeting retinitis pigmentosa caused by MERTK mutations."

Financing • Retinitis Pigmentosa

Evaluation of MERTK gene therapy in RCS rats following a single bilateral subretinal injection. (ASGCT 2025) - "These data demonstrate that in the RCS rat model of retinal degeneration, 1E10 vg/eye OPGx-MERTK effectively preserved the photoreceptors and retinal function. Disease Focus of Abstract:Eye Disorders"

Gene therapy • Preclinical • Gene Therapies • Hematological Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • MERTK

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire) - "In this rat model of retinal degeneration, subretinal administration of OPGx-MERTK (1E10 vg/eye) demonstrated effective preservation of both photoreceptors and retinal function....This preclinical study evaluated the efficacy of OPGx-MERTK in a Royal College of Surgeons (RCS) rat model, which exhibit a RPE phagocytosis defect due to a natural mutation in MERTK, following a single bilateral subretinal injection....Results from a preclinical study evaluating the safety and efficacy of OPGx-BEST1 in a canine model of BEST1 related IRD will be presented....Opus plans to commence a Phase 1/2 trial of OPGx-BEST1 in 2025 and aims to obtain preliminary data by Q1 2026."

New P1/2 trial • Preclinical • Macular Degeneration • Retinitis Pigmentosa